Published in:
01-12-2006 | Original Paper
The Use of Early and Midpoint Adenoma-Carcinoma Sequence Biomarkers in Prediction of Neoplastic Progression in Patients with a History of Colorectal Neoplasia
Authors:
Hassan Albataineh, Violeta Yordanova, Jessica Bowman, WeiLi Zhou, James Hatfield, Michael J. Lawson, Paula Sochacki, Martin Tobi
Published in:
Digestive Diseases and Sciences
|
Issue 12/2006
Login to get access
Abstract
Since significant neoplasia after initial colonoscopy is low, we conducted this pilot study to compare the predictive role for colorectal neoplasia recurrence of anti-DCC with that of Adnab-9 binding to colonic effluent of high-risk patients. DCC and Adnab-9 effluent ELISA were performed at baseline colonoscopies. The results of follow-up colonoscopies were reviewed. To ensure specificity, immunohistochemistry and Western blot was performed with anti-DCC and for Adnab-9 where optimal fixation times were also evaluated. Mean follow-up was 2.6 years. Of 21 patients, 6 of 10 who progressed to CRN and 2 of 11 who did not had a positive Adnab-9 ELISA result (P=0.08). Despite an initial good correlation with Adnab-9 ELISA results in a smaller dataset, we were unable to obtain consistent subsequent DCC immunohistochemistry or Western blot data using antibody from two different sources. However, the original dataset of Adnab-9 results was reproducible on repetition of the ELISA with a larger set of samples that included this initial dataset and optimal fixation time was 20 min. We conclude that Adnab-9 appears to be a promising prognostic marker for neoplasia in the high-risk population. Industry standards need to be developed for DCC monoclonal antibodies that may have similar utility.